PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1
Introduction: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease characterized by oxalate overproduction in the liver, leading to hyperoxaluria, calcium oxalate stones, nephrocalcinosis, progressive chronic kidney damage, kidney failure, and systemic oxalate deposition. Nedosiran, an RNA i...
Saved in:
| Main Authors: | John C. Lieske, Gema Ariceta, Jaap W. Groothoff, Graham Lipkin, Shabbir H. Moochhala, Gesa Schalk, Anne-Laure Sellier-Leclerc, Sara Estupiñan Torres, Verity Rawson, Jing Zhou, Bernd Hoppe |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024925001743 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3
by: Jaap Groothoff, et al.
Published: (2024-05-01) -
Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial
by: Jeffrey M. Saland, et al.
Published: (2024-07-01) -
Optimizing Screening Performance for the Risk of Hyperoxaluria and Urolithiasis Using the Urinary Oxalate/Creatinine Ratio: A Retrospective Analysis
by: Pierre Letourneau, et al.
Published: (2025-05-01) -
Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1
by: Cristina Martin-Higueras, et al.
Published: (2024-01-01) -
Multiomics Assessment of the Gut Microbiome in Rare Hyperoxaluric Conditions
by: Nadim Zaidan, et al.
Published: (2024-06-01)